CD274 and non-small cell lung carcinoma: Of note, PD-L1 expression is not uniformly prognostic of response to ICI therapy (86), and it has been demonstrated that NSCLC patients without PD-L1 immunohistochemical staining can still derive benefit from ICI therapy (87), supporting the now widely accepted notion that PD-L1 status by itself is insufficient to predict ICI response.